Holen Sie sich die Stockscreener-App
219.98
0.18%
-0.39
Handel nachbörslich:
219.98
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$220.37
Offen:
$221
24-Stunden-Volumen:
1.30M
Relative Volume:
0.86
Marktkapitalisierung:
$31.73B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
21.21
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
-2.16%
1M Leistung:
+10.55%
6M Leistung:
-15.04%
1J Leistung:
-23.12%
1-Tages-Spanne:
$219.97
$223.47
1-Wochen-Bereich:
$218.66
$228.55
52-Wochen-Spanne:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
219.98 | 31.79B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
391.18 | 137.90B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
180.77 | 49.60B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
73.55 | 35.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
34.12 | 30.60B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Resmed Announces Board Leadership Transition and Director Retirement - The Globe and Mail
ResMed stock slips as Q4 revenue rose 9% - ad-hoc-news.de
Resmed board set to get new lead director - HME News
RESMED INC CDI COM USD0.004 (10CDI/1SHS) To Go Ex-Dividend On August 19th, 2026 With 0.066 USD Dividend Per Share - Moomoo
UNIVEST FINANCIAL Corp Acquires Shares of 12,846 ResMed Inc. $RMD - MarketBeat
Perigon Wealth Management LLC Invests $4.60 Million in ResMed Inc. $RMD - MarketBeat
5,358 Shares in ResMed Inc. $RMD Purchased by Flputnam Investment Management Co. - MarketBeat
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor - Koreabizwire
ResMed (ASX:RMD) Faces Market Attention as Healthcare Technology Portfolio Continues to Evolve - Kalkine
ResMed (RMD) Announces Auditor Transition to PwC and Board Leade - GuruFocus
ResMed Replaces KPMG with PwC and Names Carol Burt as Lead Director - Kalkine
ResMed names Carol Burt as lead director, Ron Taylor to retire - Investing.com
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Resmed Names Carol Burt Lead Director as Ron Taylor Retires After 21 Years on Board - Quiver Quantitative
A lead director's 21-year Resmed tenure is set to end in November - Stock Titan
ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles - Yahoo Finance
ResMed Inc. (RMD) Stock Analysis: Assessing a 10% Potential Upside in Healthcare Innovation - DirectorsTalk Interviews
Could Cochlear (ASX:COH) and ResMed (ASX:RMD) Shape the Next Chapter? - Kalkine Media
87,722 Shares in ResMed Inc. $RMD Purchased by Avalon Trust Co - MarketBeat
41,381 Shares in ResMed Inc. $RMD Acquired by ABN AMRO Bank N.V. - MarketBeat
Why You Should Consider Buying ResMed Stock After Its First-Ever Annual Guide - TIKR.com
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call - Yahoo Finance
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
ResMed Inc.: Financial Data Forecasts Estimates and Expectations | RMEA | AU000000RMD6 - marketscreener.com
ResMed, Inc.: Financial Data Forecasts Estimates and Expectations | RME | US7611521078 - marketscreener.com
ResMed (ASX:RMD) Keeps Dividend Momentum Going: Keep It on Your Radar - Kalkine
ResMed to sell MatrixCare business for $490 million - Minichart
ResMed Inc. Submits Annual 10-K Report for Fiscal Year Ending June 30, 2026 - Kalkine Media
ResMed Inc. Files Annual Form 10-K Report for Fiscal Year Ended June 30, 2026 - Kalkine
ResMed Submits 2026 Fiscal Year-End 10-K Annual Report Detailing Financial and Operational Metrics - Kalkine Media
RESMED INC. : RBC RAISES TARGET PRICE TO $244 FROM $234 - webull.com
RESMED INC FY 2026: Revenue $5.65B, EPS $10.43— 10-K Summary - TradingView
How Investors May Respond To ResMed (RMD) Dividend Hike And Ventilator Recall Headwinds - simplywall.st
Handelsbanken Fonder AB Raises Stock Position in ResMed Inc. $RMD - MarketBeat
Weekly Earnings Wrap: CBA, REA Group, Westpac, Resmed and more - Morningstar Australia
ResMed Inc. Stock 12‑Month Price Target Cut to $258.47, Implies 14% Upside - TradingView
ResMed Inc. (RMD) Stock Forecasts - Yahoo Finance
J.P. Morgan Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook - Yahoo Finance
ASX healthcare share remains cheap despite mixed earnings result - Morningstar Australia
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)? - Yahoo Finance
ResMed Chairman and CEO Michael Farrell Sells 4,991 Shares Under 10b5-1 Plan - Kalkine
ResMed Inc. stock rises Tuesday, outperforms market - MarketWatch
ResMed CEO Michael Farrell sells $1.03m in company stock By Investing.com - Investing.com India
Insider Selling: ResMed (NYSE:RMD) CEO Sells $1,026,598.79 in Stock - MarketBeat
ResMed CEO Michael Farrell sells $1.03m in company stock - Investing.com
Resmed Insider Sold Shares Worth $1,026,596, According to a Recent SEC Filing - marketscreener.com
Assenagon Asset Management S.A. Grows Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Bull Thinks Five-Year Outlook Is Intact -- Market Talk - Moomoo
Ord Minnett Remains a Buy on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Macquarie Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
1.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):